Sign In
Buy CVKD
$4.19
-0.160 (-3.68%)
At Close: Jun 03, 2026
IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review
02:34am, Sunday, 28'th Dec 2025
IN8bio (NASDAQ: INAB - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two co
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis
01:12am, Monday, 22'nd Dec 2025
Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of curre
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
11:00am, Friday, 12'th Dec 2025
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ: CVKD ) entered the back half of the year with a calm, almost surgical approach to building out its foundation. Wh
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
09:45am, Friday, 12'th Dec 2025
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of curre
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
09:00am, Monday, 01'st Dec 2025
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoag
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award
08:00am, Wednesday, 19'th Nov 2025
PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoag
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
09:00am, Monday, 10'th Nov 2025
PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoag
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday
04:44am, Thursday, 30'th Oct 2025
Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
04:30pm, Monday, 29'th Sep 2025
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagula
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors
08:00am, Monday, 15'th Sep 2025
Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics ac
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Monday, 11'th Aug 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
